Healthcare News 1

• "Treating" Borderline Personality Disorders?
• $50 increase in re-imbursement will not change habits
• 22% of High Prolactin Level Artifactual
• 2nd Line Chemotherapy for Non Small Cell Lung Carcinoma (NSCLCA): A European View
• A Bedside view of ASCO Lung Cancer Abstracts: Saturday 6/4
• A Few Thoughts on the Recently Published Herceptin Studies
• A new antifolate in non small cell lung cancer? (NSCLCA)
• A new competitor in the Filler Market
• A new option for MDS and AML
• A New Playbook for Early Stage Breast Cancer?
• A new use for Gleevec?
• A novel therapy using patients' own blood may reverse a deadly component of heart disease.
• A Tale of Two Trends
• ABI-007 (Abraxane, Abraxis) in Breast Cancer
• Abilify Shows Efficacy in Borderline Personality Disorder
• Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Pl
• Actonel Nonvertebral Fracture Protection Not Dependent on BMD Change
• Additional Thoughts on Fusarium
• Addjuvant Capecitabine (xeloda)
• ADHD drugs = Speed
• ADHD Drugs and Cardiovascular Risk
• Adjuvant Herceptin in Breast Cancer
• Adjuvant therapy for early stage lung cancer
• Adriamycin and Avastin in Sarcomas: Another Use for the Antibody
• Adult population use of stimulant meds perscribed for ADHD
• Alcon Introduces a New Intraocular Lens and Gains Increased Reimbursement Benefits from Medicare
• Alcon's aspheric lens versus AMO's aspheric lens: The battle continues
• Aldosterone antagonists in heart failure
• Aldosterone Antagonists in Heart Failure - Is Their Future Limited?
• All pain pills are opiates
• Allergy Drops: Not Quite Ready for Prime Time
• Alternatives in Prevention of Breast Cancer
• ALXN's drug Soliris (eculizumab) shows strong results in treatment of Paroxysmal Nocturnal Hemoglobi
• Amgen will, most likely, win their patent dispute against Roche's CERA!
• An Extended Pattern Prostate Biopsy Technique Increases the Cancer Detection Rates
• An oral alternative in small cell lung cancer (sclca) from GSK
• An Unmet Need
• Anastomotic devices for coronary bypass surgery
• Angiostatin: New possible early treatment of DN
• Another alternative for refractory lymphomas
• Another Blow to Sanofi-Aventis' Market Share
• Another new agent in non small cell lung carcinoma (NSCLCA)
• Anthrax and cholera toxin inhibitors may lead to Novel Therapies
• Antibiotics for Asthma?
• Antiepileptic Drugs Affect Sexual Function in Men
• Antioxidant Vitamin and Mineral Supplementation May Help Prevent Prostate Cancer
• Antipsychotic Therapy Increases Hip Fracture Risk.
• Anti-tumor necrosis factor antibody therapy increases the risk of serious infection and maligancies
• Anti-VEGF drugs: expanded use in diabetic retinopathy
• ANTI-VGEF Medcines May not Be Effective to Treat Diabetic Macular Swelling
• Are all aspheric IOLs created equal?
• Are Bausch & Lomb's MoistureLoc ® related product safe?
• Are we ready? Family cluster of Avian Influenza investigated.
• Aripiprazole Well-Tolerated in Children and Adolescents at Adult Doses
• Arixtra (Fondaparinux) for Acute Myocardial Infarctions (OASIS-6)
• Arsenic in MDS??
• Arsenic's usefulness
• Artefill Nears Final FDA Approval
• Atorvastatin is associated with fatal stroke in diabetic hemodialysis patients.
• Avandia For Diabetes May Help Increase Visual Outcomes
• Avastin (Roche, Genentech) Speed Bump?
• Avastin and Lucentis: what's all the fuss about??
• AVASTIN IS THE SURPRISE WINNER AMOUNGST THE 'MACULAR DEGENERATION / ANTI-NEOGENESIS' TREATMENTS FOR NOW
• Avastin vs. Lucentis in a National Eye Institute Sponsored Trial
• Aventis: One More Treatment Option for Neovasculer
• Axon reactive b cells clonally expanded in the CSF of MS patients. J Clin Immunol 25:3,254-264
• B & L acts responsibly but ultimately shall be vindicated
• BAD NEWS FOR INSPIRE: INS 365 (diquafosol tetrasodium ophthalmic solution) for Dry Eye Does not mee
• Bausch & Lomb is Still a Name consumers count on
• Bausch and Lomb Continues to Face Serious Problems due to VIsion Threatening Fungal Eye Infections Associated with its Contact Lens Product
• Bausch and Lomb Voluntarily Recalls MoistureLoc Worldwide
• Benefits of Novartis Combination Drug Regimen
• Betaseron in Newly Emerging Multiple Sclerosis
• Bevacizumab & Erlotinib (Avastin & Tarceva) (Genentech) in Metastatic Renal Cancer
• Bevacizumab Plus Gemcitabine in Patients with Pancreatic Carcinoma
• Beyond Multifocal Intraocular Lenses: Light Adjustable Lenses
• BiDil - High Priced, but Cost-effective for Heart Failure
• Bisphosphonates for Treatment and Prevention of Bone Metastases
• Blindsided or Tunnel Vision ?
• Blindsided or Tunnel Vision ?
• Block hypertension at the first step: Novartis’ novel renin inhibitor
• Boost for Astrzenca profits with new heart failure indication
• Bortezomib an multiple myeloma
• Bortezomib in myeloma... a winner
• BRAF Mutation is Associated with More Aggressive Papillary Thyroid Cancer
• Buprenorphine (Subutex) Shows Robust Benefits for Opioid Detoxification in Adolescents
• Calhoun Vision’s Light Adjustable Lens (LAL) to enter FDA Trials in 2006
• Can We Afford Avastin (Genentech?)
• Can you tell the difference? AMGEN fears clinicians will view Aranesp and CERA as equivalent.
• Cardiovasscular trials require critical reading
• Cataract Volume Directly Related To Health Insurance Type That The Patient Carries
• CDHP vs HSA
• Cetuximab (C225) in Head and Neck (H&N) Cancer
• Changes in Adjuvant Therapy in Breast Cancer
• Changes in Cancer Therapy- are we ready?
• Chemo as a dinosaur in approaching ER+ breast cancer
• Cholinesterase Inhibitors May Not Help Alzheimer's Disease
• Chronic Kidney Disease Not limitting Use of Spironlactone in Heart Failure
• Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
• Closed Heart Surgery – The New Frontier
• Closed Heart Surgery Update
• Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
• Colony Stimulating Factors in Febrile Neutropenia
• Combination Glaucoma Drugs for glaucoma will funnel revenues away from generic beta-blockers
• Combination Therapy Benefits Patients With Hormone Refractive Prostate Cancer
• Contaminated Contact Lens Solution
• Coopervision to Distribute EPI-LASIK Products Worlwide
• Coronary artery bypass superior to stenting
• COX-2 Inhibitors and Heart Attacks - More Bad News!
• CRP levels with Valsartan Treatment
• CT angiographers predict widespread reimbursement
• CTA could become initial diagnostic test of choice
• Cures for colorectal carcinoma (CRC) with liver only mets?
• Custom Wavefront LASIK Provides Better Outcomes- November 2005 UPDATE
• Cutting Medical Costs-Outsourcing Medicine
• Cyclic PTH As Good As Daily PTH
• Cypher Stents in Acute Myocardial Infarctions: The TYPHOON Trial
• Cypher vs. Taxus stents: The REALITY Trial
• Darbepoetin (Aranesp, Amgen) and Effect on the Patient's Cancer
• DaVinci Femtosecond Laser: Real Competition for Intralase?
• Deep Brain Stimulation: The Next Gold Standard for Intractable Depression?
• Defeating planned obsolescence: The science and politics of living forever
• Defibrotide (Gentium) - Hype for new trial
• Demand for Refractive IOLs Increasing
• Dextromethorphan/Quinidine -- First Proven Treatment for Pseudobulbar Affect
• Diabetes Risk Increases with Fasting Glucose > 90
• Do All COX-2 Inhibitors Increase the Risk Of Heart Attack? More Bad News for Merck / More Good News for Tort Lawyers
• Do Long-Acting Beta Agonists Kill Asthma Patients?
• Does paracalcitol reduce proteinuria?
• Don't Forget About MAP Kinase Inhibitors
• Dont' throw out the Bisphosphonates just yet
• Drug Eluting Stent Effectiveness - What is the best metric?
• Drug Eluting Stents for Left Main Coronary Artery Disease
• Drug resistance in CLL
• Early hypertension: a potentially important marker for the efficacy of bevacizumab treatment?
• Early Results with a New Refractive Technique that will Challenge LASIK
• Eculizumab (Alexion) effective in Paroxysmal Nocturnal Hemoglobinuria(PNH)
• Efaproxiral (Allos Therapeutics) with whole brain radiation therapy (WBRT) in metastasis to the brai
• Effects of B&L's MoisturLoc Recall In the Doctor's Office
• Endovascular repair of thoracoabdominal aneurysms with hybrid procedure
• Endovascular Thoracic Aneurysm Repair
• Endovascular treatment of thoracic aneurysms
• Enhanced Efficacy Associated With Early Treatment Of Neovascular Age-Related Macular Degeneration Wi
• Epi-LASIK COMPETING WITH LASIK FOR A PIECE OF THE REFRACTIVE SURGERY PIE: Norwood Eyecare, Inc is at the Forefront of Epi-LASIK
• Epo & anemia in patients with cancer
• Epo + Neupogen in Myelodysplastic Syndrome (MDS)
• Erbitux (ImClone) in Head and Neck (H&N) Cancer
• Erlotinib in non-small cell lung cancer: who, when, where...
• Estrogen Therapy, Hot Flashes and Pain
• ET-743 in Soft Tissue Sarcomas (and future diseases?)
• Etanercept for Severe Asthma?
• etuximab: not just for EGFR (+) colorectal tumors anymore
• Exciting devices in Glaucoma Surgery
• EXEL Phase II randomized trial enrolls diabetics with nephropathy
• Exenatide as Good as Glargine but Without the Weight Gain
• Exjade and Sickle Cell Anemia(SCA)
• Experimental Bird Flu vaccine worked only about half of volunteers.
• Extensive Stage Small Cell Lung Cancer- new algorithm?
• FDA approval pending for Unique drug for weight loss and smoking cessation
• FDA Approves Alcons' Toric Acysof Lens (Implant for Cataract Surgery)
• FDA Approves First Cervical Cancer Vaccine: most important advances in women's health in recent years.
• FDA Approves Rapid-Result, In-Office Lithium Test
• FDA has ongoing concerns with Gambro Prisma CRRT device
• FDA Issues Public Health Advisory for Paxil Use in Early Pregnancy
• FDA Pediatric Advisory Committee Votes Against Black Box Warning
• FDA Sends Out Warning Letters To Allergan for Misleading Claims About Their Glaucoma Medicines
• FDA Updates Consumer on Guidant Corporation's Defibrillators
• FDA Warning Letter Issued to Alcon’s Excimer Eye Laser System (LADARVISION)
• Fenofibrate Decreases Non-fatal Heart Attack in Diabetics
• Fine Tuning Refractive Lens Surgery
• FNA biopsy OK for kids too
• From Gleevec to Desatinib
• FTY720-A New Oral Agent for Multiple Sclerosis Treatment
• Fungal Infections and Bausch & Lomb
• Fungal keratitis and contact lens solutions - beyond B&L
• Further Benefits of LASEK over LASIK Documented in Study
• Fusarium and B and L: The Saga Continues
• Fusarium keratitis: Contamination vs. Formulation Issue
• Future Therapies for Large Cell Lymphoma(DLCLA)
• Gardasil: how big is the market?
• General Anesthesia Risk is Low for Pediatric Procedures
• Genomics and the Future of Oncology
• Genzyme's EGFR mutation assay
• Get ready for nanoparticles as a delivery system for cancer treatment
• GI bowel prep implicated in causing renal failure
• GLAUCOMA CASES TO GROW GREATLY AROUND THE WORLD IN THE FUTURE
• Glucose Homeostasis Impaired in Long-term Somatostatin Analog Therapy
• Good progress with H5N1 pandemic influenza DNA vaccine
• H5N1 Human Influenza: more and more like 1918 Spanish influenza
• Heavy coffee use is associated with lower risk of type 2 diabetes.
• Hemoglobin: More isn't better
• Hepatorenal Syndrome: Terlipressin Phase III trial completes enrollment
• Herceptin/Taxotere give survival advantage in breast ca?
• High Incidence of Macular Degeneration is Found in an Elderly White Population
• Higher Dose Conformal Radiation Therapy Better at Reducing Biochemical Recurrence in Clinically Loca
• Higher Volume Centers Achieve Better Outcomes for Urologic Cancer Therapy
• Highlight on Keppra: Effective Seizure Control in Children
• Hydroxyurea vs Anagelide in Essential Thrombocythemia
• ICD Recalls: Risks of Generator Replacement Can Be Significant
• ICD Reliability
• ICD's Prevent Sudden Death
• Immunization Appears to Offer Protection Against Atopic Disease
• Implantable cardiac devices - ICD's and CRT-D - The growth is justified
• Imunization Therapy for Alzheimer's
• Incidence of Major Eye Infections after Cataract Surgery - Implications for Future of Lens Based Ref
• Increased use of minimally invasive surgery for chest aneurysms
• India is strong in Pharmaceutical Area
• Inhaled Insulin Improves Type 2 Diabetes Control
• Intensive Insulin Therapy > 3 days Beneficial in MICU Patients.
• Intensive Type 1 Diabetes Therapy May Lead to Decreased Cardiovascular Outcomes
• Intracorneal implants: A Better Treatment for Presbyopia?
• Intralase Growth in LASIK Market will Grow Slower: Experts Divided on the Benfits
• Intralase has Competition
• INTRALASE LASIK Yields Benefits for Conventional and Wavefront-Guided Procedures
• Intralase Shows More Advantages for LASIK- Thin Flap LASIK Provides Better Visual Outcomes
• Intraperitoneal therapy for ovarian cancer- state of the art
• IOL Trends - Implications for the Market
• IOL usage will increase.
• Iressa in Leukemia?
• Is Roflumilast Blockbuster Therapy or a Ho-Hum Me-Too Drug?
• Is there a ceiling???
• Is There A Future for Medical Devices in Psychiatry?
• ISTA Announces Promising Vitrase Phase III Results
• It's Hot: A New Treatment for Asthma
• Ixabepilone: A New Agent in Hormone Refractory Prostate Cancer
• KOS Finally Gets In The Game
• LASEK Presented as a Safe and Effective Method to Fix Previously Treated Eyes with RK or LASIK
• LASIK Hinge Location has no effect on Dry Eye Incidence Following LASIK Treatment
• Late Outcomes of Drug Eluting Coronary Stents
• LATEST NEWS FROM NATIONAL EYE MEETING: LASIK WILL CONTINUE TO DOMINATE BUT OTHER PROCEDURES WILL GROW
• Less Heparin Induced Thrombocytopenia (HIT) with Low Molecular Weight Heparin (LMWH?)
• Letrozole (Femara, Novartis) improves event free survival as adjuvant therapy in post menopausal bre
• Ligand's Avinza: Works Great But Will Anyone Care?
• Likely to be approved and to have a significant market
• Lipid-lowering agent use decreases stroke mortality
• Lipitor reduces carotid artery lesions within a month
• Long Acting Cytokines in a "Dose Dense" Setting.
• Low molecular weight heparin in pregnancy
• Lower is Better: A Matter of Perspective on Lipitor's IDEAL trial
• Lucentis will be the anti-VEGF drug of choice: so now what?
• Lung Cancer - The "Silent" Killer
• Lymphovascular invasion found to be significant prognostic indicator in bladder cancer
• MACUGEN (OSI/EYETECH) FOR MACULAR DEGENERATION LOSING SERIOUS GROUND TO THE COMPETITION
• Macular Degeneration linked to Clamydia
• Macular Degeneration Market Continues to Expand
• MACULAR DEGENERATION VITAMINS MAY BE BENEFICIAL
• Maintenance Rituximab (Rituxan) in relapsed lymphomas.
• Marine (Aplidine) Agent Active in Endocrine Malignancies
• McClellan and the magic AMP
• Medidur Device holds promise for treatment of diabetic retinopathy
• MedImmune's Numax: an improvement worth the price?
• Medtronic, St Jude and Guidant Defibrilator sales will increase dramatically
• Mesothelioma
• Metformin Better Than Clomiphene in Treating PCOS
• Methylphenidate Skin Patch for ADHD Reaches FDA Advisory Committee
• Mifepristone: Utilzing a Novel Mechanism of Action to Demonstrate Rapid and Effective Anti-Psychotic
• Minimally invasive diagnosis of solid tumors
• Minimally invasive diagnosis of solid tumors
• Minor Blip in the Road
• Modafinil (Sparlon) Safe and Effective for Child and Adolescent ADHD
• Monthly Ibandronate as Effective as Daily.
• More User Friendly Alternative for Neuroendocrine Tumors?
• Much Ado About Nothing: The Fusarium Story
• Muraglitazar Increases Risk of Death and Major Adverse Cardiovascular Events.
• Muscle damage from statin treatment.
• My analysis of the three oral Vitamin D analogs available for treatment of hyperparathyroidism in CKD
• Netoglitazone Lowers Glucose Without Adversely Affecting Bone.
• Never ask a barber whether you need a haircut – Confuscious
• NEW ADVERSE ALLERGIC REACTIONS WITH MACUGEN (Eyetech) REPORTED TO THE FDA
• NEW AGENTS
• new algorithm for myeloma!?
• New and Better Treatment for Migraines
• New and Better Treatment for Mucositis
• New Anti-CD 22 Antibody Therapy for Lupus
• New Anti-CD20 Monoclonal Antibodies
• New Approach to Treatment of Alzheimer's Disease
• New Competion for Intralase in Laser Flap Creation: The DaVinci Femtosecond Laser Microkeratome Rec
• New drug for an unmet need
• New drugs may protect against worsening of Parkinson's disease
• New drugs out of old drugs
• New drugs out of old drugs
• New findigs on the immune response against the polyomaviruses JC and BK: implications for natalizumab
• New Generation Bisphosphonate Reduces Skeletal-Related Events in Hormone Refractory Prostate Cancer
• New Immunotherapeutic for Prostate Cancer
• New Information About Tysabri
• New life for an old agent:GlaxoSmithKline (GSK) finally finds a real use for Topotecan
• New Macular Degeneration Medicines May Serve Many Useful Purposes: VEGF and SDF-1 in the Pathogenesi
• New Monoclonal Antibody in Colon Cancer (CRC)
• New onsite coated DES with promising results
• New standard of care for metastatic bladder cancer
• New treatment for Parkinson's disease
• New treatment for pseudobulbar affect
• New Treatment for the Prevention of Seasonal Major Depressive Episodes in Patients with a Diagnosis of Seasonal Affective Disorder
• New twist for arsenic in cancer
• New use for Lamotrigine
• New use for Topamax
• New Vitamin D Compound Builds Cortical Bone
• New Warnings Ahead for Lilly’s Strattera?
• Nexavar (Bayer)
• Niche for new phosphate binder unclear
• NitroMed Inc new drug approved by FDA with patent until 2020
• No new PML cases after stopping natalizumab
• Non-Invasive Screening of the Skin
• Not just a novelty
• Novartis combination strategy
• Novartis Heart Combo - Will PDP plans pay for combo?
• Novartis report on two drug safety
• Novel Device for Preventing Exercise Asthma in Winter
• Novel treatment of Alport Disease: Stem cell therapy repairs basement membrane defect
• NxStage Increasing Convenience of Home Hemodialysis
• NxStage Medical:Boom or Bust?
• Octreotide LAR Better Than Lanreotide SR
• On-X on target ?
• Ophthalmological Uses of Tumor Necrosis Factors
• Optimism on MedCath Premature
• Options for Refractory CML (Chronic Myelogenous Leukemia) and Perhaps Better 1st line therapy in future
• Oral Fludarabine (Fludara)
• Oral Form of Nalmefene Shows Benefit in Pathological Gambling
• Oral Memantine: The Next Frontier in Glaucoma Therapy
• Oral Therapy for Iron (Fe) Overload in Thalassemia and More!
• Oral Zemplar in Predialysis Patients
• Ortho vs Amgen: a draw
• Other New Uses for Revlimid
• Out-Patient Therapy for Metastatic Melanoma. A New Standard?
• Oxaliplatin: New Uses For A Familiar And Somewhat Friendly Agent
• Panitumumab: a great leap forward or 'so what'?
• Pas-Port Connector: Do we really want it?
• PATIENTS AND OPHTHALMOLOGISTS ABANDON BAUSCH AND LOMB CONTACT LENS SOLUTIONS OVER CONCERN OF BLINDING FUNGAL EYE INFECTIONS
• Percutaneous Closure of Patent Foramen Ovales for the Treatment of Migraine Headaches
• Perspective on bifocal intraocular lenses.
• PET scan: an early prognosticator in Hodgkin's disease.
• Pfizer’s Chantix Obtains FDA-Approval for Smoking Cessation
• Pfizer's Anti Glaucoma Eye Drop (Xalatan/Latanaprost) Continues to Dominate Field
• PFO closure to treat migraines?
• Phakic Lenses Heal Faster than LASIK!
• Pioglitazone Decreases Macrovascular Disease But Increases Heart Failure.
• Pomegranate juice shown to have significant beneficial effect in recurrent prostate cancer
• Possible Changes in Reimbursement for ICDs at Subspecialty Hospitals
• Post Remission Therapy in Acute Myelogenous Leukemia(AML)
• Potential new therapy in Chronic Lymphatic Leukemia (CLL)
• Potential treatment for axonal peripheral neuropathy
• Pregabalin : A New and Effective Approach for Treating Generalized Anxiety Disorder
• Pregabalin, weight gain, and diabetes
• Presbyopia Correcting IOLS will Pique Patients Interest
• Prevention of Central Vein catheter Venous Thrombosis
• primary study used to defend Ketek's safety is wrought with fraud, error, and other inconsistencies
• Priority Review Granted for Pfizer Smoking Cessation Drug
• Probucol Delays Progression of Diabetic Nephropathy.
• Progressive Multifocal Leukoencephalopathy and Natalizumab
• Promising treatment for Parkinson's disease
• Psychosocial Interventions are Tops--everything else is Icing on the Cake
• PTH Therapy Needs Alendronate Therapy Afterward
• PTHrP is Safe and Well-tolerated At Very High Doses.
• Pulsed Dye Vs Excimer Laser for Psoriasis
• QR-333 May Be Effective in Diabetic Neuropathy
• Quetiapine for Bipolar Depression
• RA drugs --- Benefits clearly outweigh the risks.
• Radical prostatectomy offers promising survival in clinical T3 prostate cancer
• Raltitrexed (Tomudex) + Cisplatin in Mesothelioma
• Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 ug Every 2 Weeks)
• Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
• Ranexa a unique anti-anginal drug
• Rapidly Growing Initial Sales of Revlimid
• Rasilez - novel renin inhibitor
• Reduciton of neovascularization using Rosigiltazone
• Refractive Lens Exchange Will Dominate
• Regression of Coronary Artery Disease
• Regression of Coronary Atherosclerosis with Rosuvastatin (Crestor)
• Renal Solutions Receives FDA Approval for New Portable Dialysis Machine
• Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression
• Restasis Daily (Allergan), Safe and Well-Tolerated in Dry Eye Patients
• ReStor gradually becoming more popular
• ReStor IOL Not Catching on as Fast as Predicted
• Results of Rheopheresis for Macular Degeneration not Impressive
• Revia (Naltrexone) Outperforms Campral (Acamprosate) for Alcohol Dependence
• Review of calcimimetic and calcilytic article
• REVISED: Abciximab- One Less Drug For Acute Stroke
• Revlimid (lenalidomide, Celgene) in Multiple Myeloma
• Rheumatoid Arthritis
• Rimonabant (Accomplia) - The magic pill ?
• Rimonabant Improves Cardiovascular Risk Factors
• Risedronate Prevents Hip Fracture in Male Stroke Victims
• Risk of Prostate Cancer in Men on Testosterone Supplementation
• Risks of Novantrone Treatment of Multiple Sclerosis
• Risks of Plavix Usage
• Rituxan in Post Transplant Lymphoproliferative Disorders(PTLPD)
• Robotic Heart Surgery – Feasibility
• Robots - Enhancing Procedures or Justifying Existance
• Rosiglitazone with minimal benefit in overweight Type 1 diabetics.
• Ruboxistaurin Decreases Diabetic Visual Loss.
• S-1 ... more play in the United States?
• SAFTEY CONCERNS FOR HEART FAILURE DRUG FROM SCIOS
• Scleral implants: A better treatment for presbyopia?
• Sea squirts may come in handy one day
• Sensipar seeking upstream indication in stage 3 and 4 CKD markets
• Side Effects of Trileptal
• Silicone Breast Implant Approval Closer
• Single Dose Carboplatin is as Effective as Radiotherapy in Stage I Seminoma
• Smaller Incisions Mean Better Outcomes
• Soft-Tissue Sarcomas in Adults and Their Treatment
• Specialty spending keeps soaring
• STAR*D Data Demonstrate Clinical Benefits for Augmentation and Switching Strategies in Major Depression
• Stathmin: A New Genetic Target for Conditioned Fear and Anxiety
• Statins - The Newest Panacea
• STATINS, THE EXPANDING PANACEA?
• Stem Cells for Heart Failure: Is There a Risk of Arrhythmias?
• Stent Wars - Panacea or DES-ease
• Stents - Here to stay!
• Sterotaxis: Magnetic Navigation for Atrial Fibrillation Ablation
• Study suggests continuum of prostate cancer risk for all PSA values
• SU011248 -- getting ready for prime time
• Sunitinib (Pfizer), a new player in renal cancer
• Support Growing for Selective Laser Trabeculoplasty (SLT) as a first-line treatment for Glaucoma
• Surgeons Remain Skeptical of Scleral Surgery for Presbyopia
• Sutent (Pfizer) approved for kidney cancer and Gleevec refractory gastrointestinal stromal tumors (G
• Tacrolimus-Safe Treatment for Atopic Dermatitis
• Talotrexin in Non-small cell lung cancer
• Tarceva in HCC (hepatocellular carcinoma)
• Tarceva in Lung Cancer
• Tarceva in Pancreatic Cancer
• Tarceva with Gemzar in Pancreatic Carcinoma-ODAC recommends approval
• Tecnis and aspheric IOLs: implications for future
• The 3PL vs. Wholesale battle heats up
• The changing oncology distribution business
• The doctor won’t see you now.
• The expanding market for intra-ocular lenses
• The Future of Photodynamic Therapy (PDT)
• The Genetics of AMD: implications and possible cures for the future
• The Immune System and Immunotherapy in the Treatment of Cancer
• The INTRINSIC RV Study
• The LABA Controversy Continues
• The REALITY trial – Cypher vs. Taxus
• The risk of infection is overblown
• The Selegiline Patch: Will MAOI Treatment of Depression Return?
• The silencing of the labs
• The stent revolution - Who's Da Boss
• The Synchrony IOL: Multifocal IOLs Beware?
• The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a rev
• The world of cell cycle inhibitors
• Therapeutic Applications of Genomics
• Therapy for "refractory" Chronic Myelogenous Leukemia (CML)
• Therapy for Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Therapy for Waldenstrom's Macroglobulinemia
• Therapy in refractory chronic lymphatic leukemia (CLL).
• This points out a fact we have known for years, that in ERA positive women chemotherapy has a very small benefit advantage when compared to hormona
• Thumbs Down on Non-prescription Nasal Steroids
• Tissue Adhesive Effective for Sealing Clear Corneal Cataract Wounds
• Toll Like Receptors (TLRs) and TLR-based therapies and drugs
• Topamax: An Emerging Treatment for PTSD?
• Topical Sirolimus for Psoriasis
• Torcetrapib and Atorvastatin
• Tositumomab (Bexxar)- in Low Grade and Transformed Non-Hodgkins Lymphoma (NHL)
• Totally Robotic: Is this the future?
• Transcriptional therapeutics
• Transplant in Myeloma?
• Traumatic Brain Injury
• Treating Severe Asthma with Ciclesonide: Is the New Kid on the Block Better?
• Treatment of Left Main Coronary Artery Disease
• Treatment of Left Main Coronary Artery Disease
• Tumor vascular targeting
• Turning a Negative Into a Positive - Pioglitazone
• Tyrosine Kinase Inhibitors (TKI) in Bronchioloalveolar Lung Cancer (BAC)
• Tyrosine Kinase Inhibitors (TKI's) in Glioblastomas
• Uphill for BiDil
• Urine Telomerase: A better TRAP to detect bladder cancer
• Use of fluorescent in situ hybridization for the detection of bladder cancer.
• Use of Hormine Blockers in Breast Cancer
• Use of Taxus Stents for Primary PCI in ST elevation Myocardial Infarctions
• Use of Zerenex in ESRD as a phosphate binder
• Vagal nerve stimulation treatment for cerebellar tremor
• Valsartan and CRP
• Vasopressin Influences Aldosterone Secretion in Primary Hyperaldosteronism.
• Velcade in Bronchioloalveolar (BAC) Lung Cancer
• Velcade in Small Cell Lung Cancer (SCLC)
• Vildagliptin and Metformin Improve Diabetic Beta Cell Function.
• VISIAN Implantable Contact Lens (Staar Surgical) Finally Approved by FDA
• Vitamin D prolongs survival in advanced prostate cancer
• Vitamin D Receptor Gene Variant Associated with Severe Diabetic Retinopathy
• Vitrase (ISTA pharmaceuticals) Appears Effective in Management of Vitreous Hemorrhage in the Eye
• Walgreen's future: PBM + Chain Merger?
• Watson Pharmaceutical's Acquisition of Andrx
• Weak data generates intriguing hypothesis
• Wearing Contact Lenses to Improve Your Vision While You Sleep
• Weekly Compared to Every Three Week Taxotere.
• What Goes Around Comes Around: PRK is not dead yet.
• What is keeping the Home Hemodialysis market from expanding?
• What is normal blood pressure? The line is a changin’.
• What is the reference standard for pancreatic cancer?
• What's the best treatment option for adjuvant colon cancer?
• Where does the future of gefitinib (Iressa) lie?
• Will EU and US pharma distribution converge?
• Will Fusarium Karatitis Outbreak Change Prescribing Practices?
• Will Surface Ablation take the place of Lasik
• Will unbundling crush pharmacy channel profits?
• Will Velcade be First Line Therapy for Multiple Myeloma? Sort of Maybe..
• Xibrom for Cataract Surgery: Should Alcon and Allergan be worried?
• Yet another victory for Herceptin
• ZoMaxx Drug-Eluting Stent for Coronary Atery Disease
• ZOSTAVAX: New Vaccine Dramatically Reduces Risk of Shingles
• Zyprexa in Prodromal Psychosis: Weighing the Risks and Benefits